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Discrimination between the human 
prostate normal and cancer cell 
exometabolome by GC-MS
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Serum prostate-specific antigen (PSA) is currently the most used biomarker in clinical practice for 
prostate cancer (PCa) detection. However, this biomarker has several drawbacks. In this work, an 
untargeted gas chromatography-mass spectrometry (GC-MS)-based metabolomic profiling of PCa cells 
was performed to prove the concept that metabolic alterations might differentiate PCa cell lines from 
normal prostate cell line. For that, we assessed the differences in volatile organic compounds (VOCs) 
profile in the extracellular medium (exometabolome) of four PCa cell lines and one normal prostate 
cell line at two pH values (pH 2 and 7) by GC-MS. Multivariate analysis revealed a panel of volatile 
metabolites that discriminated cancerous from normal prostate cells. The most altered metabolites 
included ketones, aldehydes and organic acids. Among these, we highlight pentadecane-2-one and 
decanoic acid, which were significantly increased in PCa compared to normal cells, and cyclohexanone, 
4-methylheptan-2-one, 2-methylpentane-1,3-diol, 4-methylbenzaldehyde, 1-(3,5-dimethylfuran-2-yl)
ethanone, methyl benzoate and nonanoic acid, which were significantly decreased in PCa cells. The PCa 
volatilome was markedly influenced by the VOCs extraction pH, though the discriminant capability was 
similar. Overall, our data suggest that VOCs monitoring has the potential to be used as a PCa screening 
methodology.
Prostate cancer (PCa) is the second leading cause of cancer-related death in men in most western countries1 
and for 2017, 26,730 resulting deaths are predicted for USA alone2. Prostate-specific antigen (PSA) is currently 
the most used biomarker for PCa detection, in combination with digital rectal examination (DRE)3. However, 
the role of serum PSA levels as a screening tool for PCa meets with important limitations. Although raised PSA 
levels (i.e., >4.0 ng/mL) are undoubtedly associated with the presence of PCa, benign conditions, such as pros-
tatitis and benign prostatic hyperplasia (BPH), which are common in the elderly, also cause elevated serum PSA. 
Consequently, there is a relatively high frequency of unnecessary prostate biopsies, an invasive procedure which is 
expensive and uncomfortable for the cancer suspects4. Moreover, a significant proportion of men with PSA levels 
within the normal range harbor PCa (up to 22%) and a significant number of these show pathologic features of 
tumor aggressiveness5–8. Indeed, 21% of men with positive end of study biopsies enrolled in the Prostate Cancer 
Prevention Trial (PCPT) had serum PSA levels between 2.6 and 3.9 ng/mL and 15.4% of the tumors found in 
men with PSA levels < 2.5 ng/mL were high grade cancers9. The PSA test for PCa diagnosis has a area under the 
curve (AUC) of 0.682 and considering a cut-off of 4.1 ng/ml this biomarker shows a specificity of 93.8% and a 
sensitivity of 20.5%1. Furthermore, PSA is unable to differentiate aggressive from indolent PCa, which may lead 
to overtreatment10,11. Indeed, a large US-based trial found no benefit of PSA screening in reducing PCa-related 
mortality12 and even the large European trial that found a moderate benefit (approx. 20%) acknowledged that 
1410 men would have to be screened and additional 48 cases of PCa would need to be treated to avoid a single 
death from PCa13. Besides the human cost, implementing widespread PSA screening for PCa might also lead to 
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double of the total financial costs associated with PCa management14. Due to these limitations, the use of PSA for 
populational screening has been challenged15.
Although several molecular tests have been developed over the years and some have already obtained FDA 
approval16, accurate early detection of PCa remains an unmet need. Thus, discovery and validation of novel, more 
specific and cost-effective biomarkers that might improve early PCa diagnosis and more precisely forecast its 
clinical behavior in an individual basis is an important research aim.
Metabolomics is a powerful analytical tool in oncology, endowing novel biomarkers and therapeutic targets, 
as cancer cells have the capacity to modify many homeostatic systems within the body and, consequently, change 
the production, use and levels of many metabolites17,18. A metabolomic approach may allow for the discovery of 
biochemical signatures, and, consequently, of differences between cancer and healthy metabolic phenotypes17 in 
non-invasive samples. An early intervention is possible using metabolomics, since it is believed that metabolic 
alterations precede neoplastic proliferation11.
Several different matrices may be used in PCa metabolomics studies, but the most common are biofluids (e.g., 
urine and serum/plasma), tissues and cell lines. Generally, when the chosen matrix is a biofluid and/or a tissue 
it is very important to be aware that metabolic profile can be altered by factors not related to cancer cell metab-
olism, like age, diet, drugs, chronobiological variations, among others, which are very important to control to 
obtain reliable results. On the other hand, experiments performed in cultured cell lines have several advantages 
compared to the use of urine or plasma, overcoming these problems17. In fact, the use of cell lines in preliminary 
studies have important advantages, as cell lines allow to circumvent several important confounding factors, like 
age, diet, drugs, chronobiological variations, among others19–21. In addition, cell lines have a perfectly defined cell 
state which allows for the analysis of a target metabolic status. So, we believe that cell lines are the ideal matrix 
for hypothesis generation and to unveil unchanged metabolic signature originated directly from cells, metabolic 
alterations that do not appear in studies using animal models or human subjects, due to sample biological com-
plexity, may be revealed19–21. Notwithstanding, this in vitro model presents some limitations, particularly the fact 
that cultured cells fail to reproduce the complex cell–cell and cell–matrix interactions in the tumour microen-
vironment and these interactions are very important for metabolic alterations occurring with tumor progres-
sion20,22. For these reasons, the findings obtained in in vitro studies need further confirmation and validation in 
biofluids from PCa patients.
Volatilome is defined as the analysis of the volatile profile of a biological system, being accomplished by the 
evaluation of the volatile organic compounds (VOCs)23. VOCs correspond to a carbon-based chemical group, 
with low molecular weight and high volatility. These compounds are excreted (exometabolome) from the human 
body in several tissues, accumulated and/or eliminated and can reflect the metabolic condition of an individ-
ual24,25 and, therefore, have the potential to provide new biomarkers for cancer detection. Since VOCs are the 
end products of cell metabolism, the volatilome can provide information about intracellular metabolic status. 
Alterations in VOCs profile may be related to modifications in gene activation, gene expression, proteins and 
activity of enzymes involved in metabolic pathways26,27.
Importantly, the volatilome analysis does not require cell disruption, which allows the use of the same 
cells at different times28. The most commonly used method to analyse VOCs is the Headspace-Solid Phase 
Microextraction/Gas Chromatography-Mass Spectrometry (HS-SPME/GC-MS), which involves simple and 
rapid sample preparation, allowing high-throughput screening, has a good sensitivity and does not require a 
concentration step before analysis29,30. Moreover, VOCs can be detected in several different matrices, including 
exhalated breath and urine, particularly interesting for clinical practice use due to their non-invasive nature23,31.
Some reports have already focused on the application of VOCs analysis in different cancers, namely breast32, 
lung31, head and neck33, esophago-gastric34, colorectal skin35, skin36, liver37 and renal23, proving to be able to dis-
criminate cancer from normal samples. With great interest to this study, some reports determining VOCs in urine 
of PCa patients showed significantly differences from urines of control individuals38,39.
The main objective of this study is to perform the volatile profiling of four different PCa cell lines (22RV1, 
PC3; DU145; LNCaP) and one normal prostate epithelial cell line (PNT2) to prove the concept that VOCs ema-
nated into the extracellular medium may discriminate PCa cells from normal prostate cells. VOCs extraction is 
performed at two different pH values, pH 7 (natural pH of prostate cells’ medium) and pH 2 because it is well 
established that tumor microenvironment is acidic to promote tumor progression and metastasis40. This strategy 
allows to obtain a more comprehensive evaluation of PCa volatile profile and to infer which pH is optimum for 
VOCs extraction and detection. VOCs significantly altered as a consequence of PCa metabolism will integrate 
a panel of candidate biomarkers for early detection of PCa that may, in the future, be translated and validated in 
other biological matrices (e.g. urine) and used in clinical practice. Furthermore, cell lines included in this study 
exhibit different hormone-dependency and potential for invasiveness, which allowed for extending our investiga-
tion on the metabolites responsible for discriminating PCa cell lines according to tumour androgen-deprivation 
sensitivity and aggressiveness. To the best of our knowledge, this work is the first to analyze VOCs profile in 
human PCa cell lines.
Results
In this study, we performed a metabolomic untargeted approach, at two different pHs, pH 7 and pH 2, to evaluate 
alterations in the volatilome of PCa cell lines (22RV1, PC3, DU145 and LNCaP) when compared with normal 
prostate cell line (PNT2). A multivariate analysis (MVA) approach was applied to evaluate the ability of vola-
tilome to discriminate the different cell lines used in this study. Figure 1 shows the representative chromatograms 
of the volatile profile obtained at pH 7 and pH 2. A total of 239 and of 221 features were detected in the chroma-
tograms obtained at pH 7 and pH 2 samples, respectively (Fig. 1).
The reproducibility of the analytical method is evidenced by the QCs cluster in PCA scores plot 
(Supplementary Fig. 1). Furthermore, the MVA analysis (principal component analysis (PCA) and partial least 
www.nature.com/scientificreports/
3SCIENTIFIC RePoRtS |  (2018) 8:5539  | DOI:10.1038/s41598-018-23847-9
squares discriminant analysis (PLS-DA)) proved that VOCs can discriminate PCa cell lines from normal prostate 
cell line and between the different PCa cell lines at both pHs as showed in Fig. 2.
To evaluate which VOCs were responsible for this separation, each cancer cell line was compared separately 
with the normal cell line, using a MVA supervised analysis (PLS-DA), namely 22RV1 vs. PNT2, PC3 vs. PNT2, 
DU145 vs. PNT2 vs. LNCaP vs. PNT2. An optimal separation between PCa cell lines and normal cell line was 
observed at both pH values (Supplementary Fig. 2 (pH 7) and Supplementary Fig. 3 (pH 2)).
To prove the robustness of the discrimination, all PLS-DA models were validated through permutation test 
(200 random permutations of Y-observations, 2 components). The results of this validation showed that all cre-
ated models were robust for the discrimination between PCa cell lines and the normal prostate cell line (Fig. 3B 
and Supplementary Table 1).
All VOCs with Variable Importance to the Projection (VIP) values higher than 1 were considered potentially 
relevant for the separation among cell lines. Hence, at pH 7 a total of 23 VOCs were considered relevant to differ-
entiate 22RV1 from PNT2 and 32 at pH 2; at pH 7, 16 VOCs were considered relevant to differentiate PC3 from 
PNT2 and 25 at pH 2; at pH 7, 27 VOCs were considered relevant to differentiate DU145 from PNT2 and 32 at 
pH 2; and, finally, at pH 7, 21 were considered relevant to differentiate LNCaP from PNT2 and 24 at pH 2 (Tables 
1 and 2).
To confirm the importance of these metabolites, univariate analysis was performed as explained below (see 
statistical analysis section). A total of 8 VOCs proved to be relevant to differentiate 22RV1 from PNT2 in the 
results obtained at pH 7 and 11 at pH 2; 8 VOCs proved to be relevant to differentiate PC3 from PNT2 at pH 
7 and 19 at pH 2; 7 VOCs proved to be relevant to differentiate DU145 from PNT2 at pH 7 and 13 at pH 2; 
and 7 proved to be relevant to differentiate LNCaP from PNT2 at pH7 and 13 at pH 2 (Tables 1 and 2). At 
pH 7, one VOC stood out, namely, pentadecan-2-one since this VOC revealed to be important for the separa-
tion among all PCa cell lines and normal cell line (Fig. 3A, Table 1 and Fig. 4). However, several other VOCs 
were tentatively identified (Supplementary Table 2) and were also able to discriminate between cancer and nor-
mal cell lines, namely, 1,3-benzothiazole, 3,7-dimethyloct-7-en-1-ol (22RV1 vs PNT2, PC3 vs PNT2, DU145 
vs PNT2), 2-methylundecanal, (PC3 vs PNT2, DU145 vs PNT2 and LNCaP vs PNT2), 2,7-dimethyloctan-1-ol 
(PC3 vs PNT2), 2-(4-methylcyclohex-3-en-1-yl)propan-2-ol (PC3 vs PNT2), decan-1-ol (DU145 vs PNT2), 
1-methoxypropan-2-yl acetate (LNCaP vs PNT2), and 1,4-xylene (LNCaP vs PNT2) (Table 1).
Figure 1. Chromatograms from quality control samples (QCs) at pH 7 and pH 2 (1: 3-methylbut-3-en-2-ol; 2: 
1,4-xylene; 3: 2,7-dimethyloctan-1-ol; 4: 2-(4-methylcyclohex-3-en-1-yl)propan2-ol ; 5: 3,7-dimethyloct-7-en-
1-ol; 6: 1,3-benzothiazol; 7: decan-1-ol; 8: pentadecan-2-one; 9: cyclohexanone; 10: 4-methyheptan-2-one; 11: 
2-methylpentan-1,3-diol; 12: 4-methylbenzaldehyde; 13: methyl benzoate; 14: nonanoic acid; 15: decanoic acid).
Figure 2. PCA scores scatter plot obtained for the HS-SPME/GC-MS chromatograms of all samples (PNT2: 
green; 22RV1: dark blue; PC3: light blue; DU145: red; LNCaP: yellow) (A) at pH 7 (R2X = 0.445) and (B) at pH 
2 (R2X = 0.582). In both PCA it is possible to observe the discriminant capability of the volatilome analyzed by 
HS-SPME/GC-MS, as each cell line forms an independent cluster.
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At pH 2, 8 VOCs stood out, namely, cyclohexanone (Fig. 5), 4-methylheptan-2-one, 2-methylpentane-1,3-diol, 
4-methylbenzaldehyde (Fig. 5), 1-(3,5-dimethylfuran-2-yl) ethanone, methyl benzoate, nonanoic acid and deca-
noic acid (Fig. 4) as they revealed to be important for the separation between all PCa cell lines and normal cell line 
(Table 2). Other VOCs unveiled specificity for each cell line namely, 4-methylpent-3-en-2-one (22RV1 vs PNT2, 
PC3 vs. PNT2, DU145 vs PNT2), 5-methylheptan-2-one (PC3 vs PNT2, DU145 vs PNT2 and LNCaP vs PNT2), 
phenylethanol (22RV1 vs PNT2, PC3 vs PNT2, DU145 vs PNT2), 4-methylnonanoic acid (22RV1 vs PNT2 and 
LNCaP vs PNT2), benzyl acetate (22RV1 vs PNT2 and LNCaP vs PNT2), 5-methyl-2-propan-2-ylcyclohexan-1-ol 
(PC3 vs PNT2 and LNCaP vs PNT2), 1-ethoxypentane (DU145 vs PNT2 and LNCaP vs PNT2), methyl nonano-
ate (22RV1 vs PNT2), 2-ethoxy-2-methylbutane (PC3 vs PNT2), hexanoic acid (PC3 vs PNT2), phenylmethanol 
(PC3 vs PNT2), 2,4-dimethylheptan-1-ol (PC3 vs. PNT2), benzoic acid (PC3 vs PNT2), 6-pentyloxan-2-one (PC3 
vs PNT2) (Table 2). Some unidentified VOCs (codified as unknown 1, 2, 3…) were also found as important for 
the discrimination between cancer and normal cell lines.
ROC curves were performed for all significantly altered VOCs (Fig. 3A), and the results revealed that all 
significantly altered metabolites have a AUC higher than 0.5 and several metabolites showed a AUC equal to 1 
(Tables 1 and 2).
The sensitivity and specificity of the discriminative sets of metabolites obtained for each pair were also calcu-
lated and the results reveal that the discriminant sets have a sensitivity and specificity of 100% or very close to this 
value for discriminating the PCa cell lines from the normal prostate cell line (Supplementary Table 3).
Discussion
Comparative analysis of VOCs in PCa and prostate normal cell lines obtained at pH 7. In this 
work, we showed the potential of VOCs at physiological pH to discriminate several PCa cell lines from a normal 
prostate cell line. The results disclosed significantly altered VOCs in all PCa cell lines when compared with the 
normal cell line (Table 1), with special emphasis for pentadecan-2-one that was found increased in all PCa cell 
lines. Importantly, this VOC seems to be cell-specific as it is not present in the culture medium, and, therefore, it 
should be investigated in future as a promising biomarker for PCa.
In addition, our findings further demonstrate that it is possible to discriminate PCa cells with different degrees 
of aggressiveness based on VOCs profiling. For instance, 2,7-dimethyloctan-1-ol and 2-(4-methylcyclohex-
3-en-1-yl)propan-2-ol were found significantly decreased in the culture medium of PC3 cells, which have high 
metastatic potential (Table 1). The significant increase of decan-1-ol levels was a characteristic alteration of the 
cell line with moderate metastatic potential (DU145), whereas the significant increase of 3-methylbut-3-en-
2-ol, 1-methoxypropan-2-yl acetate and 1,4-xylene levels were characteristic of the cell line with the lower met-
astatic potential (LNCaP) (Table 1). It was also possible to discriminate androgen responsive from androgen 
non-responsive cell lines using 3,7-dimethyloct-7-en-1-ol, since this metabolite was only significantly decreased 
in androgen non-responsive cell lines (PC3, DU145 and 22RV1) (Table 1). Interestingly, 22RV1 that is an andro-
gen receptor positive cell line was able to survive and grow in a culture medium not supplemented with androgen, 
resulting in the development of an androgen-independent phenotype cell line, possibly by a mechanism similar to 
the one occurring in clinical practice after hormone deprivation therapy. This explanation was already addressed 
by other researchers41.
The integration of VOCs in metabolic pathways is, at present, hard to perform, because studies with vola-
tilome are scarce and very recent. However, using the human metabolome database (HMDB)42–44, it was possible 
to see if some of those metabolites found in our samples were already found by other researchers in biological 
matrices. The Supplementary Table 2 enables to do the interconnection between the significantly altered identi-
fied metabolites in our in vitro disease model and this database42–44.
Figure 3. (A) Example of assessment of the diagnostic performance through ROC analysis obtained for 
PC3 vs PNT2 at pH7 (2-pentadecanone (AUC = 1) and 2-methylundecanal (AUC = 0.84)) and at pH2 
(4-methylheptan-2-one (AUC = 0.89) and benzoic acid (AUC = 0.77). (B) Statistical validation of the PLS-DA 
model for PC3 vs PNT2 at pH 2 by permutation testing (200 permutations; 2 components).
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The increase in pentadecan-2-one observed in all PCa cell lines is in accordance with previously reported 
increase in ketone levels in urine from PCa patients38, as well as in other cancer cell lines37,39,45,46. This find-
ing may be explained by the increased fatty acid β-oxidation and protein metabolism, used to produce energy, 
which lead to ketones production47. In particular, the metabolism of C15:0 long-chain fatty acids may originate 
pentadecan-2-one in PCa cell lines48. Furthermore, ketones can also be produced from the respective secondary 
alcohols37. Alteration in the activity of alcohol dehydrogenase49 and cytochrome P450 (CYP 450) activities30 can 
also be related to alteration in ketone and aldehydes levels, since hydrocarbons can be metabolized to aldehydes 
or ketones in the human body via these enzymes50. In our study, alterations in the aldehydes and hydrocarbons 
levels were also observed, which reinforce the connection between the observed changes and alterations in the 
activity of these two enzymes.
Chemical name 
(IUPAC) or 
common name
22RV1 vs PNT2 PC3 vs PNT2 DU145 vs PNT2 LNCaP vs PNT2
p value
Variation ± 
uncertainty
ES ± 
ESSE AUC p value
Variation ± 
uncertainty ES ± ESSE AUC p value
Variation ± 
uncertainty
ES ± 
ESSE AUC p value
Variation ± 
uncertainty
ES ± 
ESSE AUC
Alcohols
3-Methylbut- 
3-en-2-ol ↑  ↑ 0.0018
P ↑34.78  
± 7.88
↑1.48  
± 0.88 0.86
2,7-Dimethyloctan 
-1-ol (dihydro-
citronellol)
>0.05 ↓ ↓ <0.0001P ↓74.48  ± 7.90
↓5.91  
± 1.84 1 >0.05 ↑ ↑ >0.05
↓32.61  
± 28.71 ↓
2-(4- 
Methylcyclohex- 
3-en-1-yl)propan- 
2-ol (α-Terpineol)
<0.0001P ↓58.47  ±4.51
↓7.22  
± 2.18 1
3,7-Dimethyloct-7- 
en-1-ol (α- 
citronellol)
0.0096 ↓48.80  ± 20.30
↓1.26  
± 0.85 0.81 <0.0001
P ↓58.00  
± 21.18
↓1.52  
± 0.88 0.98 <0.001
P ↓73.13  
± 23.15
↓1.86  
± 0.95 1 >0.05
↑137.92  
± 28.06
↑1.14  
± 0.84
Decan-1-ol 0.0251 ↑18.24  ± 6.65
↑1.01  
± 0.84 0.77
Esters
1-Methoxypropan- 
2-yl acetate >0.05
↓ 30.40  
± 16.70
↓0.85  
± 0.81 >0.05
↑72.03  
± 8.56
↑1.11  
± 0.85 0.0447
↑70.57  
± 18.49
↑ 1.11  
± 0.83 0.74
Ketones
Pentadecan-2-one <0.0001P ↑ 203.50  ± 5.40
↑7.34  
± 2.22 1 <0.0001
P ↑848.29  
± 6.06
↑10.53  
± 3.07 1 0.0007
P ↑58.66  
± 10.04
↑1.89  
± 0.96 0.94 <0.0001
P ↑73.12  
± 9.26
↑2.27  
± 1.01 0.98
Aromatic hydrocarbon like
1,4-Xylene >0.05 ↓10.74  ± 6.87 ↓ >0.05
↑89.15  
± 32.29 ↑ 0.0011
P ↑182.61  
± 24.11
↑1.56  
± 0.89 0.88
Naphthalene 0.0011P ↑ 49.20  ± 8.80
↑1.76  
± 0.92 0.88
Aldehydes
2-Methylundecanal 0.0029P ↑ 58.67  ± 11.00
↑1.54  
± 0.89 0.84 0.0037
↓31.88  
± 10.31
↓ 1.41  
± 0.88 0.84
↑71.77  
± 15.15
↑1.37  
± 0.86 0.82
Others
1,3-Benzothiazole <0.0001P ↓75.00  ± 6.80
↓6.91  
± 2.10 1 <0.0001
P ↓70.22  
± 7.35
↓7.03  
± 2.13 1 0.0348
↓23.35  
± 8.56
↓1.02  
± 0.84 0.70 <0.0001
P ↓69.91  
± 7.11
↓5.96  
± 1.86 1
Unknowns
Unknown 2 0.0414 ↓32.26  ± 15.95
↓0.92  
± 0.83 0.71
Unknown 3 >0.05 ↓20.36  ± 12.46 ↓ 0.0204
↑30.56  
± 10.07
↑1.04  
± 0.83 0.78
Unknown 7 0.0011P ↓ 58.30  ± 22.20
↓1.46  
± 0.88 0.88 >0.05 ↓ ↓ 0.0010
P ↓23.26  
± 6.27
↓1.63  
± 0.91 0.85 0.0023
P ↓34.10  
± 15.37
↓1.05  
± 0.83 0.85
Unknown 8 0.0024 ↑14.60  ± 3.80
↑1.43  
± 0.87 0.84 >0.05
↓9.18  
± 5.37 ↓ >0.05 ↑ ↑
Unknown 12 0.0338 ↑20.39  ± 7.80
↑0.96  
± 0.84 0.76
Unknown 13 <0.0001P ↑63.50  ± 4.70
↑4.03  
± 1.38 1 <0.0001
P ↑177.78  
± 6.14
↑6.03  
± 1.87 1 >0.05 ↑ ↑ 0.0016
P ↑36.55  
± 7.49
↑1.63  
± 0.90 0.85
Unknown 14 0.0003P ↑58.60  ± 10.10
↑1.76  
± 0.92 0.91 <0.0001
P ↑181.87  
± 4.63
↑8.10  
± 2.42 1 >0.05 ↓ ↓
Table 1. List of VOCS, from the analysis of samples prepared at pH 7, selected as important in discriminating PCa 
cell lines from normal cell lines (22RV1 vs PNT2, PC3 vs PNT2, DU145 vs PNT2 and LNCaP vs PNT2). VOCs are 
characterized by their IUPAC name. Values for p-values percentage of variation, effect size (ES), standard error 
(ESSE) and area under the curve (AUC) are represented for each VOC. PAlterations remaining significant after 
Bonferroni correction, with cutoff p value of: 2.17 × 10−3 (0.05 divided by 23 analyzed VOCs) for 22RV1 vs PNT2; 
3.12 × 10−3 (0.05 divided by 16 analyzed VOCs) for PC3 vs PNT2; 1.85 × 10−3 (0.05 divided by 27 analyzed VOCs) 
for DU145 vs PNT2; and 2.38 × 10−3 (0.05 divided by 21 analyzed VOCs) for LNCaP vs PNT2.
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Chemical name 
(IUPAC) or common 
name
22RV1 vs PNT2 PC3 vs PNT2 DU145 vs PNT2 LNCaP vs PNT2
p value
Variation ± 
uncertainty
ES ± 
ESSE AUC p value
Variation ± 
uncertainty
ES ± 
ESSE AUC p value
Variation ± 
uncertainty
ES ± 
ESSE AUC p value
Variation ± 
uncertainty
ES ± 
ESSE AUC
Alcohols
2-Methylpentane-
1,3-diol 0.0105
↓10.70  
± 3.80
↓1.17  
± 0.84 0.81 <0.0001
P ↓45.10  
± 5.81
↓3.95 
± 1.36 1 <0.0001
p ↓25.79  
± 3.95
↓2.95 
± 1.14 0.99 <0.0001
p ↓24.26  
± 5.53
↓1.97 
± 0.95 0.92
Phenyl-methanol >0.05 ↑35.50  ± 19.60 ↑ 0.0189
↓33.69  
± 15.30
↓1.04 
± 0.83 0.82 >0.05 ↑ ↑ >0.05 ↑ ↑
2,4-Dimethylheptan-
1-ol >0.05
↑32.70  
± 20.10 ↑ 0.0210
↓35.32  
± 16.50
↓1.02 
± 0.83 0.79 >0.05 ↓
↓82.41 
± 7.28 >0.05 ↑ ↑
Phenylethanol <0.0001P ↓38.10  ± 7.90
↓2.36  
± 1.02 0.97 <0.0001
P ↓69.81  
± 8.12
↓5.20 
± 1.66 1 <0.0001
p ↓38.79  
± 8.76
↓2.16 
± 0.99 0.92
5-Methyl-2-propan-
2-ylcyclohexan-1-ol 
(DL-menthol)
>0.05 ↓ ↓ 0.0068 ↓45.82  ± 18.48
↓1.27 
± 0.85 0.83 0.0447
↓27.4  
± 14.89
↓0.84 
± 0.81 0.74 0.0019
p ↓42.10  
± 13.39
↓1.57 
± 0.89 0.91
Esters
Methyl benzoate <0.0001P ↓42.20  ± 3.90
↓5.51  
± 1.74 1 <0.0001
P ↓53.12  
± 4.10
↓6.95 
± 2.11 1 <0.0001
p ↓51.06  
± 5.58
↓4.84 
± 1.57 1 <0.0001
P ↓22.45  
± 4.27
↓2.33 
± 1.01 0.94
Benzyl acetate <0.0001P ↓35.17  ± 6.10
↓2.75  
± 1.10 1 0.0090
↑23.73  
± 7.0
↑1.19 
± 0.84 0.79
Methyl nonanoate <0.0001P ↑366.00  ± 7.90
↑6.46  
± 1.98 1
Ketones
4-Methylpent-3-en-
2-one <0.0001
P ↓47.20  
± 7.10
↓3.44  
± 1.24 0.99 <0.0001
P ↓62.38  
± 7.88
↓4.54 
± 1.50 1 <0.0001
p ↓48.54  
± 9.03
↓2.80 
± 1.11 0.95
Cyclohexanone <0.0001P ↓81.10  ± 7.00
↓7.72  
± 2.32 1 <0.0001
P ↓50.48  
± 5.88
↓4.53 
± 1.50 1 <0.0001
p ↓82.41  
± 7.28
↓7.59 
± 2.28 1 <0.0001
P ↓80.15  
± 7.33
↓7.19 
± 2.18 1
4-Methylheptan-
2-one <0.0001
P ↓28.60  
± 6.30
↓2.10  
± 0.97 0.92 0.0003
P ↓38.37  
± 8.84
↓2.11 
± 0.98 0.89 <0.0001
p ↓36.06  
± 6.93
↓2.51 
± 1.05 0.95 0.0014
p ↓26.30  
± 7.86
↓1.52 
± 0.88 0.84
5-Methylheptan-
2-one <0.0001
P ↓51.58  
± 6.11
↓4.48 
± 1.48 1 <0.0001
p ↓27.47  
± 5.97
↓2.10 
± 0.97 0.94 0.0014
p ↓20.36  
± 5.95
↓1.50 
± 0.88 0.86
1-(3,5-Dimethyl-
furan-2-yl) ethanone <0.0001
P ↓47.80  
± 5.30
↓4.79  
± 1.56 1 <0.0001
P ↓41.51  
± 5.09
↓4.06 
± 1.38 1 <0.0001
p ↓46.45  
± 6.01
↓3.96 
± 1.36 1 0.0003
p 21.78  
± 5.50
↓1.75 
± 0.91 0.88
6-Pentyloxan-2-one 
(δ-decalactone) >0.05 ↓ ↓ 0.0006
P ↓39.93  
± 11.98
↓1.640 
± 0.90 0.88 >0.05 ↓ ↓ >0.05 ↑ ↑
Alkane hydrocarbon
2-Ethoxy-2-
methylbutane >0.05
↓26.60  
± 19.90 ↓ 0.0342
↓38.26  
± 19.77
↓0.94 
± 0.81 0.74 >0.05 ↓ ↓
1-Ethoxy-pentane 0.0056 ↑ ↑ 0.0010p ↓31.16  ± 9.21
↓1.58 
± 0.89 0.88 0.0001
p ↓35.34  
± 8.69
↓1.95 
± 0.95 0.92
Aldehydes
4-Methyl-
benzaldehyde 0.0022
↓10.60  
± 3.00
↓1.47  
± 0.88 0.81 <0.0001
P ↓38.00  
± 2.98
↓6.20 
± 1.92 1 <0.0001
p ↓32.04  
± 2.39
↓6.29 
± 1.94 1 0.0005
p ↓18.39  
± 4.31
↓1.85 
± 0.93 0.87
Organic acids
Hexanoic acid >0.05 ↓ ↓ 0.0092 ↓40.00  ± 16.66
↓1.18 
± 0.84 0.84 >0.05 ↓ ↓ >0.05 ↑ ↑
Benzoic acid >0.05 ↓ ↓ 0.0331 ↓37.17  ± 17.66
↓1.01 
± 0.82 0.77 >0.05 ↓ ↓ >0.05 ↑ ↑
Nonanoic acid <0.0001P ↓55.60  ± 8.80
3.47  
± 1.25 1 <0.0001
P 59.85  
± 7.41
4.54 ± 
1.50 1 <0.0001
p ↑31.32  
± 6.29
↑2.33 
± 1.02 0.97 <0.0001
P ↑66.28  
± 7.67
↑5.09 
± 1.64 1
4-Methyl-nonanoic 
acid <0.0001
P ↑1217.10  
± 11.70
↑5.79  
± 1.81 1 <0.0001
P ↑3242.3  
± 10.90
↑65.79 
± 2.07 1
Decanoic acid 0.0027 ↑71.10  ± 14.00
↑1.47  
± 0.88 0.83 <0.0001
P ↑250.44  
± 18.10
↑2.42 
± 1.03 0.98 <0.0001
p ↑268.37  
± 8.66
↑5.21 
± 1.67 1 0.0122
74.50  
± 19.00
↑1.13 
± 0.83 0.80
Unknowns
Unknown 16 >0.05 ↓ ↓ 0.0321 ↓30.20  ± 14.74
↓0.95 
± 0.82 0.79
Unknown 18 <0.0001P ↓94.90  ± 11.80
↓6.05  
± 1.88 1 <0.0001
P ↓59.85  
± 7.41
↓4.54 
± 1.50 1
Unknown 19 >0.05 ↓20.90  ± 17.10 ↓ 0.0004
P ↓38.38  
± 10.98
↓1.71 
± 0.91 0.92 >0.05 ↓ ↓ >0.05 ↑ ↑
Table 2. List of VOCS, from the analysis of samples prepared at pH 2, selected as important in discriminating PCa 
cell lines from normal cell lines (22RV1 vs PNT2, PC3 vs PNT2, DU145 vs PNT2 and LNCaP vs PNT2). VOCs are 
characterized by their IUPAC name. Values for p-values, percentage of variation, effect size (ES), standard error 
(ESSE), and area under the curve (AUC) are represented for each VOC. ↑, VOCs increased; ↓, VOCs decreased 
in the extracellular medium of PCa compared with normal cell line PAlterations remaining significant after 
Bonferroni correction, with cutoff p value of 1.56 × 10−3 (0.05 divided by 32 analyzed VOCs) for 22RV1 vs PNT2; 
2.00 × 10−3 (0.05 divided by 25 analyzed VOCs) for PC3 vs PNT2; 2.38 × 10−3 (0.05 divided by 21 analyzed VOCs) 
for DU145 vs PNT2; and 2.08 × 10−3 (0.05 divided by 24 analyzed VOCs) for LNCaP vs PNT2.
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The alteration in aldehydes (e.g. 2-methylundecanal) profiling is common in urine of PCa patients38 and in 
cancer cell lines from colon and lung37,39,51. This altered profile may be associated with an alteration in lipid perox-
idation, induced by the increased ROS levels, characteristic of cancer cell metabolism and inflammation38,47,51,52. 
Beyond lipid peroxidation, aldehydes can also result from amino acid and carbohydrate catabolism53,54. An alter-
native explanation for the aldehyde levels variation can be related to alterations in aldehyde dehydrogenases 
(ALDHs) activity, responsible for the aldehydes oxidation to carboxylic acids53,54. Furthermore, ALDHs are 
involved in cellular proliferation, differentiation and survival, and in the cellular response to oxidative stress. The 
alteration in ALDHs was associated with PCa and other cancers progression53,54.
A significant alteration in aromatic hydrocarbons, such as naphthalene and 1,4-xylene, in the culture media 
of cancer cell lines was also observed. Importantly, the alteration in 1,4-xylene levels observed in our study is 
in concordance with previously reported alteration in 1,4-xylene in exhaled breath from PCa patients55 and in 
urines from head and neck cancer patients56. The presence of these molecules was previously related with the 
presence of ROS and oxidative stress47,57,58. So, the increase in aromatic hydrocarbons in cancer cell lines media 
can be an indicator of an increase in ROS activity, which could lead to lipid peroxidation and consequently to cell 
membrane damage59.
In our study, several alcohols, such as 3-methylbut-3-en-2-ol, 2,7-dimethyloctan-1-ol, 2-(4-methylcyclohex-
3-en-1-yl)propan-2-ol, 3,7-dimethyloct-7-en-1-ol and decan-1-ol were altered in PCa cell lines; this alteration 
in alcohols levels may be due to the alteration in hydrocarbon metabolism, being alcohols end-products of this 
metabolism50,58. The β-oxidation used by cancer cells to produce acetyl-CoA, that can be incorporated in Krebs 
cycle, may be other important source of alcohols. Thus, one may hypothesize that decan-1-ol can be associated 
with the synthesis of a medium-chain fatty acid, namely capric acid (C10:0), for energy production42–44. Other 
well described characteristic of cancer cells is their rapid growth, which implies an increase of cellular membrane 
synthesis. The alcohols may be metabolized to carboxylic acids and these acids further used to the synthesis of 
cellular membrane precursors60. Another possible explanation for the increased levels of some alcohols is the 
induction of the cytochrome P450 enzymes that occurs during carcinogenesis56. CYP 450 can hydroxylate several 
VOCs, including the alkanes produced during lipid peroxidation of polyunsaturated fatty acids, which leads to 
the production of corresponding alcohols56. Alcohols can also be produced by enzymatic reduction of aldehydes 
by alcohol dehydrogenases37.
Comparative analysis of VOCs in PCa and normal cell lines obtained at pH 2. It is well established 
that tumor microenvironment is acidic40, to promote tumor progression and metastasis. The biochemical mech-
anisms related with acidic pH include hypoxia, excessive glycolysis, hyperexpression of carbonic anhydrase and 
Figure 4. Boxplots from the metabolite pentadecan-2-one, increased in all PCa cells when compared with 
PNT2 (normal cells), after univariate analysis, obtained at pH 7 and boxplots from the metabolite decanoic acid, 
increased in all PCa cells when compared with PNT2 (normal cells), after univariate analysis, obtained at pH 2.
Figure 5. Boxplots from cyclohexanone and 4-methylbenzaldeyde, metabolites decreased in all PCa cells when 
compared with PNT2 (normal cells), after univariate analysis, obtained at pH 2.
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poor perfusion40. The important role of acidic pH in tumor microenvironment highlights the interest of studying 
the volatilome at pH 2.
As for physiological pH, the volatilome obtained at pH 2 was able to differentiate PCa cell lines from normal 
prostate cell line, taking into account the quality of the two PLS-DA models (R2X = 0.526; R2Y = 0.457; Q2 = 0.437 
for pH 2 vs R2X = 0.445; R2Y = 0.463; Q2 = 0.446 for pH 7). Although the discriminant capability of these two 
models is similar, the discriminant metabolites were not the same at the two medium pH, showing that acidifi-
cation of the samples markedly influences the prostate cell volatilome (e.g. detection of volatile organic acids). 
As described by other authors30, the detected volatilome was markedly different in the two pHs in study, which 
highlights the importance of the study of volatilome at different pH, to obtain a comprehensive picture of cells 
volatilome.
Seven VOCs, namely 2-methylpentane-1,3-diol, 1-(3,5-dimethylfuran-2-yl)ethanone, methyl benzoate, nona-
noic acid, cyclohexanone, 4-methylbenzaldehyde (Fig. 5), and 4-methylheptan-2-one were significantly decreased 
in the extracellular medium of all PCa cell lines when compared with normal cell line (Table 2). On the other 
hand, decanoic acid (Fig. 4) was increased in the extracellular medium of all PCa cell lines. Based on the altered 
volatile profile among cell lines in study, it was also possible to discriminate PCa cells with different aggres-
siveness. For example, 2-ethoxy-2-methylbutane acid, hexanoic acid, phenylmethanol, 2,4-dimethylheptan-1-ol, 
benzoic acid, and 6-pentyloxan-2-one were significantly decreased in the extracellular medium of high meta-
static potential cell line (PC3), whereas 1-ethoxypentane was significantly decreased specifically in moderate 
and low metastatic potential cell line (DU145 and LNCaP, respectively). Moreover, some VOCs can discriminate 
androgen responsive cell lines from androgen non-responsive cell lines. For instance, 4-methylpent-3-en-2-one 
and phenylethanol (Table 2) were only significantly decreased in the androgen non-responsive cell lines (PC3, 
DU145 and 22RV1). Importantly, 4-methylnonanoic acid, hexanoic acid and 6-pentyloxan-2-one were absent in 
the cellular medium, suggesting its origin from cellular metabolism, thus unveiling great potential as candidate 
biomarkers to be further validated in biofluids from PCa patients.
The majority of the VOCs significantly altered were decreased in cancer cell lines in comparison with normal 
cell line, being this observation previously made in other metabolomic studies with urine from PCa patients38,61. 
The cancer cells may use these metabolites for their metabolic processes more extensively then normal prostate 
cells38,61, converting these VOCs in other metabolites that cannot be detected by our methodology.
Comparison of the metabolites found in our samples at pH 2 was made with those already described by 
other researchers in biological matrices42–44 (Supplementary Table 2). The significant alterations in the levels of 
decanoic acid in the PCa cells study is in concordance with previously reported in serum of PCa patients62. Also, 
alterations in decanoic acid, phenylmethanol and nonanoic acid were associated with melanoma63. The significant 
alteration in the levels of 4-methylheptan-2-one study is in concordance with previously reported in urines from 
head and neck cancer patients56.
Similarly to pH 7, in the volatile profile obtained at pH 2, it was observed a significant alteration in the levels 
of ketones, aldehydes and alcohols associated with PCa. Significant alterations in levels of some esters and organic 
acids were also observed.
Esters can be found naturally in fats and may be originated from acids and alcohols during lipid hydrolysis, 
which may explain the reduction in the levels of these VOCs, observed in PCa cell lines50. So, the alteration in 
esters levels and organic acids levels can be related as ester metabolism can lead to organic acid production and 
acid metabolism can lead esters formation37.
Alteration in organic acids was previously described in urine and serum of PCa patients61,62. Organic acids 
can be involved in several biological processes, including cell signaling, energy storage, energy source, and cel-
lular membrane integrity61. As aforementioned, alteration in ALDHs function can also be associated with the 
alteration in the organic acid levels, as this enzyme can catalyze the conversion of aldehydes into organic acids37.
Conclusion
Our results highlight the capability of volatilome analysis to identify potential biomarkers to be used in PCa 
diagnosis, since at both analyzed pH the VOCs profile was able of differentiate all cell lines in study. One of the 
most problematic drawbacks of PSA is its inability to differentiate aggressive PCa from indolent PCa. Our results 
reveal that through the evaluation of the alterations in volatile profile of PCa cell lines it is possible to differentiate 
PCa cells with different aggressiveness. The use in clinical practice of a biomarker or a panel of biomarkers able 
to make this differentiation will bring major benefits for PCa patients, improving PCa management and circum-
venting the problem of overtreatment. Furthermore, volatilome also prove be able to differentiate PCa cell lines 
with different hormonal dependency.
The influence of pH in the volatilome was also evaluated and is a parameter to be considered. Acidification of 
the samples markedly influenced the volatile composition (e.g. detection of volatile organic acids), hence, to have 
a more comprehensive analysis of cell volatilome it is advantageous to use both pH.
The integration of VOCs in specific metabolic pathways is still very difficult, needing more studies to com-
pletely accomplish this goal. Nevertheless, our results indicate that PCa cell lines have lipid metabolism altered, 
mainly in lipid peroxidation, lipid hydrolysis, synthesis of fatty acid and fatty acid β-oxidation. The obtained 
results also suggest the modification in the activity of some important enzymes, namely, alcohol dehydrogenase, 
cytochrome P450 and aldehyde dehydrogenase.
It is important to emphasize that for a possible use in the clinical practice it is mandatory to prove the trans-
latability of these results to in vivo samples, preferentially urine. Further studies are still needed to confirm our 
results, and find out a non-invasive, sensible and specific biomarker (or set of biomarkers) for prostate cancer.
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Materials and Methods
Chemicals. All chemicals and reagents were of analytical grade. RPMI-1640 medium, 4-fluorobenzaldeyde 
(internal standard) and all GC-MS standard compounds were purchased from Sigma-Aldrich Co. (St. Louis, MO, 
USA). The antibiotic mixture penicillin/streptomycin (10000 U/mL/10000 µg/mL), heat inactivated fetal bovine 
serum (FBS) and trypsin 0.25%-EDTA were purchased from GIBCO Invitrogen (Barcelona, Spain). Hydrochloric 
acid (HCl) and sodium hydrogen carbonate were obtained from Merck (Darmstadt, Germany). Sodium chloride 
(NaCl) was from VWR (Leuven, Belgium).
Cell Culture. PCa human immortalized cell lines (PC3, 22RV1, DU145 and LNCaP) and human normal 
prostate epithelium immortalized cell line (PNT2) were provided by Portuguese Oncology Institute-Porto 
(IPO-Porto) and their respective characteristics are shown in Supplementary Table 4. In brief, 22RV1 and LNCaP 
are cell lines from prostate carcinoma with androgen receptor (AR) expression, whereas PC3 and DU145 cells 
lines are androgen unresponsive. PC3 is a cell line from grade IV adenocarcinoma with high metastatic potential; 
DU145 is a cell line from prostate carcinoma, with moderated metastatic potential; and LNCaP is a cell line from 
prostate carcinoma with low metastatic potential. The selection of the cells lines was performed to allow to cover 
an extended range of PCa with different features, namely different aggressiveness and hormonal dependency. 
Furthermore, it was possible to use the same culture media to grow all cell lines. The use of different culture 
media, in this kind of studies, may be a confounding factor, once different culture media might have different 
effects on cellular metabolic profiles, thereby compromising the comparison of the VOCs profiles64.
All cell lines were grown in RPMI-1640 supplemented with 10% of FBS and 1% of penicillin/streptomycin, 
maintained at 37 °C and 5% CO2 in 75 cm2 culture flasks and grown to 80% confluency, before each passage. For 
all cell lines the same passages were used. All cell lines were routinely tested for Mycoplasma spp. contamination 
(PCR Mycoplasma Detection Set, Clontech Laboratories).
VOCs collection and extraction. The experiments were carried out during 4 consecutive passages (pas-
sages 3 to 6) with triplicates for each passage, after an adaptation stage of at least 3 passages for all cell cultures. 
After the cells had reached near confluence, the medium was discarded and replaced with 15 mL of fresh RMPI-
1640 medium, and incubated at 37 °C and 5% CO2 for 48 h, together with three blanks (cellular medium without 
cells treated exactly as the study samples). After 48 h, the extracellular medium from flasks with cells and blanks 
were collected, centrifuged (2000 × g for 10 min at 4 °C), the supernatant separated from the pellet, and divided 
into two equal aliquots (one for analysis at pH 7 and another for analysis at pH 2). To prevent the loss of VOCs, all 
collection steps were performed on ice and immediately frozen at −80 °C until analysis.
Stored samples were thawed slowly at low temperatures, in order to minimize the loss of VOCs65. All samples 
were analyzed at the pH of the medium culture around pH 7 (pH = 7.675 ± 0.28) and at pH 2 (pH = 2.156 ± 0.31). 
For acidification, a fixed volume of 5 M HCl was added. For GC-MS analysis, 2 mL of sample were placed into a 
10 mL glass vial with the internal standard (4-fluorobenzaldehyde (10 µg/mL)) and NaCl (≈0.59 g). The extrac-
tion was performed according to the conditions previously determined65. Simultaneously, quality control (QCs) 
samples were also prepared using the same protocol. QCs samples were a pool of all samples and blanks used in 
the study. To avoid the frequent freezing and thawing, that could change the VOCs fingerprint, the QCs samples 
were divided in several aliquots and each aliquot was defrost prior to GC-MS analysis.
GC–MS analysis. The data acquisition was performed in a Scion-436 gas chromatograph coupled to a 
Bruker SQ (single quadrupole) equipped with a SCION SQ ion trap mass detector and a Bruker Daltonics MS 
workstation software version 6.8, with a Rxi-5Sil MS (30 m × 0.25 mm × 0.25 µm) column from RESTEK. A 
CombiPAL automatic autosampler (Varian, Palo Alto, CA) was used and experimental conditions were previously 
described65. The carrier gas used was helium C-60 (Gasin, Portugal) (flow of 1 mL/min) and the injector port 
was heated to 230 °C. The analysis was performed in Full Scan mode. The oven temperature was fixed at 40 °C for 
1 min, then increasing to 250 °C (rate 5 °C/min), held for 5 min, then increasing to 300 °C (rate 5 °C/min) and held 
for 1 min. The transfer line temperature was 280 °C, manifold temperature was 50 °C and the trap temperature 
was 180 °C. The mass range was 40–350 m/z, with a scan rate of 6 scan/s. All samples were injected randomly65.
To ensure reproducibility, QCs samples were injected at the same conditions on every 6 samples (three times 
per day)66.
The identification of VOCs was accomplished by using standards, the National Institute of Standards and 
Technology (NIST 14) data base spectra library and by comparing experimental Kovats index and Kovats index 
from literature (Supplementary Table 2).
Statistical analysis. Prior to statistical analysis of results, all chromatograms were pre-processed. This 
pre-processing includes: baseline correction, peak detection, chromatogram deconvolution and alignment, per-
formed using the program MZmine67. The parameters used to accomplish these were: RT range 2.8–34.0 min; 
m/z range 50–250; MS data noise level 1.0 × 104; m/z tolerance 0.5; chromatogram baseline level 1.0 × 103; peak 
duration range 0.02–0.30 min. Also, all ions with a relative standard deviation68 greater than 30% as well as ions 
(m/z) coming from the column, the fiber, among others were manually removed from the matrix. The obtained 
data was normalized for the total area of the chromatograms.
The statistical treatment includes unsupervised (PCA) and supervised analyzes (PLS-DA). All VOCs with 
VIP values greater than one were considered potential relevant for the separation among cell lines. For these 
relevant compounds, univariate analysis was performed, using Shapiro-Wilk test, to determine normality dis-
tribution of data, and unpaired Student’s t-test with Welch correction test, for normal distribution, or unpaired 
Mann-Whitney test, for non-normal distribution, to calculate the p value. In addition, the percentage of variation, 
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uncertainty of the percentage of variation, and effect size and the standard error were calculated69. Bonferroni 
correction was used to adjust p-values. For all significantly (p value < 0.05, effect size higher than the standard 
error and % variation superior to uncertainty) altered metabolites, receiver operating characteristic10 curves were 
computed and AUC (area under the curve) was also calculated (using MetaboAnalyst 3.0).
Finally, to confirm the robustness of the PLS-DA models, all PLS-DA models were validated through permu-
tation test (200 random permutations of Y-observations, 2 components). The sensitivity and specificity of the 
discriminant sets of metabolites obtained from all comparison pairs at pH 7 and pH 2 were also calculated (using 
MetaboAnalyst 3.0).
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